Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia

In the phase 2b/3 DIVERSITY trial, 3 months treatment with dabigatran was noninferior to standard of care (SOC) for acute venous thromboembolism (VTE) in children. In a single-arm, phase 3, secondary VTE prevention study, up to 12 months dabigatran use was associated with favorable safety. Dabigatra...

Descripción completa

Detalles Bibliográficos
Autores principales: Brandão, Leonardo R., Tartakovsky, Igor, Albisetti, Manuela, Halton, Jacqueline, Bomgaars, Lisa, Chalmers, Elizabeth, Luciani, Matteo, Saracco, Paola, Felgenhauer, Judy, Lvova, Olga, Simetzberger, Monika, Sun, Zhichao, Mitchell, Lesley G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661433/
https://www.ncbi.nlm.nih.gov/pubmed/36150047
http://dx.doi.org/10.1182/bloodadvances.2021005681

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661433/
https://www.ncbi.nlm.nih.gov/pubmed/36150047
http://dx.doi.org/10.1182/bloodadvances.2021005681

Ejemplares similares